Imunon, Inc.
IMNN Healthcare Biotechnology
Imunon, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $500,000.00. In the quarter to June 2026, EPS grew 71.1% and free cash flow fell 4.24%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow IMNN
Imunon, Inc. (IMNN) Piotroski F-score
Imunon, Inc.'s Piotroski F-score for fiscal 2022 is 2 out of 9: 2 of nine tests of profitability, leverage and efficiency passed, down from 3 in fiscal 2021.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2022 | 2 | (1.00) |
| FY2021 | 3 | (1.00) |
| FY2020 | 4 | 2.00 |
| FY2019 | 2 | (1.00) |
| FY2018 | 3 | (2.00) |
| FY2017 | 5 | 2.00 |
| FY2016 | 3 | — |
How fiscal 2022’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (60.83%) | (37.23%) | Fail | 0 |
| Positive operating cash flow | (23.10m) | (16.22m) | Fail | 0 |
| Rising return on assets | (60.83%) | (37.23%) | Fail | 0 |
| Cash flow above net income | 12.80m | 4.55m | Pass | 1 |
| Falling long-term leverage | 0.08 | 0.10 | Pass | 1 |
| Rising current ratio | 3.66 | 7.67 | Fail | 0 |
| No new shares issued | 547,900 | 416,300 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.01 | 0.01 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 2 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| LEXX Lexaria Bioscience Corp. compare | 4 |
| EVGN Evogene Ltd. compare | 4 |
| TRAW Traws Pharma, Inc. compare | 4 |
| ORGS Orgenesis Inc. compare | 3 |
| IMNN Imunon, Inc. | 2 |
| CANF Can-Fite Biopharma Ltd compare | 2 |
| ENVB Enveric Biosciences, Inc. compare | — |
| NRSN NeuroSense Therapeutics Ltd. compare | — |
| ALZN Alzamend Neuro, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover